HomeCompareHUM vs BSX

HUM vs BSX: Dividend Comparison 2026

HUM yields 2.13% · BSX yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HUM wins by $69.2K in total portfolio value
10 years
HUM
HUM
● Live price
2.13%
Share price
$166.00
Annual div
$3.54
5Y div CAGR
46.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$89.4K
Annual income
$29,002.59
Full HUM calculator →
BSX
BSX
● Live price
3.18%
Share price
$62.93
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.2K
Annual income
$0.32
Full BSX calculator →

Portfolio growth — HUM vs BSX

📍 HUM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHUMBSX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HUM + BSX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HUM pays
BSX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HUM
Annual income on $10K today (after 15% tax)
$181.27/yr
After 10yr DRIP, annual income (after tax)
$24,652.20/yr
BSX
Annual income on $10K today (after 15% tax)
$270.14/yr
After 10yr DRIP, annual income (after tax)
$0.27/yr
At 15% tax rate, HUM beats the other by $24,651.93/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HUM + BSX for your $10,000?

HUM: 50%BSX: 50%
100% BSX50/50100% HUM
Portfolio after 10yr
$54.8K
Annual income
$14,501.46/yr
Blended yield
26.46%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BSX right now

HUM
Analyst Ratings
14
Buy
27
Hold
2
Sell
Consensus: Hold
Price Target
$235.00
+41.6% upside vs current
Range: $146.00 — $345.00
Altman Z
4.0
Piotroski
6/9
BSX
Analyst Ratings
2
Strong
38
Buy
3
Hold
Consensus: Buy
Price Target
$108.35
+72.2% upside vs current
Range: $94.00 — $130.00
Altman Z
3.9
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HUM buys
13
BSX buys
6
PoliticianChamberTickerTypeAmountDate
Julia Letlow🏢 House$HUM▼ Sell$1,001 - $15,0002026-02-10
Gilbert Cisneros🏢 House$BSX▲ Buy$1,001 - $15,0002026-02-10
Gilbert Cisneros🏢 House$BSX▲ Buy$1,001 - $15,0002026-01-30
Markwayne Mullin🏛 Senate$BSX▲ Buy$15,001 - $50,0002025-12-29
Markwayne Mullin🏛 Senate$BSX▲ Buy$15,001 - $50,0002025-12-29
Gilbert Cisneros🏢 House$BSX▼ Sell$1,001 - $15,0002025-12-24
John Boozman🏛 Senate$BSX▼ Sell$1,001 - $15,0002025-12-17
John Boozman🏛 Senate$BSX▼ Sell$1,001 - $15,0002025-12-17
Gilbert Cisneros🏢 House$BSX▲ Buy$1,001 - $15,0002025-11-18
Gilbert Cisneros🏢 House$HUM▼ Sell$1,001 - $15,0002025-11-12
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHUMBSX
Forward yield2.13%3.18%
Annual dividend / share$3.54$2.00
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR46.1%-50%
Portfolio after 10y$89.4K$20.2K
Annual income after 10y$29,002.59$0.32
Total dividends collected$63.4K$321.00
Payment frequencyquarterlyquarterly
SectorHealthcareHealthcare
Analyst consensusHoldBuy
Analyst price target$235.00$108.35

Year-by-year: HUM vs BSX ($10,000, DRIP)

YearHUM PortfolioHUM Income/yrBSX PortfolioBSX Income/yrGap
1← crossover$11,012$311.56$10,859$158.91+$153.00HUM
2$12,251$468.45$11,700$80.63+$551.00HUM
3$13,820$711.61$12,559$40.60+$1.3KHUM
4$15,883$1,096.11$13,459$20.36+$2.4KHUM
5$18,715$1,720.11$14,411$10.20+$4.3KHUM
6$22,793$2,767.44$15,425$5.10+$7.4KHUM
7$28,990$4,601.98$16,507$2.55+$12.5KHUM
8$39,012$7,992.19$17,664$1.28+$21.3KHUM
9$56,428$14,685.03$18,901$0.64+$37.5KHUM
10$89,380$29,002.59$20,225$0.32+$69.2KHUM

HUM vs BSX: Complete Analysis 2026

HUMHealthcare

Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, and home solutions services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2021, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

Full HUM Calculator →

BSXHealthcare

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Full BSX Calculator →
📬

Get this HUM vs BSX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HUM vs SCHDHUM vs JEPIHUM vs OHUM vs KOHUM vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.